Randomized Trialmoderate evidence
Effects of semaglutide on cardiac structure and function in heart failure with preserved ejection fraction and obesity: a pre-specified cardiac magnetic resonance substudy of the CAMEO-SEMA trial.
Nature medicine·November 8, 2026·PMID 43000112
Why it mattersObesity-related HFpEF is common and difficult to treat; semaglutide's hemodynamic benefits may be mediated by improvements in cardiac structure and function. This mechanistic insight supports the use of GLP-1 receptor agonists in this population and may guide monitoring of cardiac remodeling.

The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled